MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Argireline Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Argireline (acetyl hexapeptide-8) is a synthetic topical anti-wrinkle peptide, Ac-EEMQRR-NH2, that mimics the N-terminal end of SNAP-25 and competitively interferes with SNARE-complex assembly, reducing acetylcholine release and softening dynamic expression lines in a mild, reversible way unlike botulinum toxin (PMID 18498523). It is used cosmetically as a 5-10% serum applied twice daily; a 10% emulsion reduced wrinkle depth up to ~30% over 30 days, and randomized data support modest benefit (PMID 23417317). Its main limitation is poor skin penetration: as a charged, hydrophilic peptide, typically under 1% crosses the stratum corneum. There is no medical injectable or oral dose; the subcutaneous reconstitution numbers here are an educational measurement reference only. Argireline is a cosmetic ingredient, not an FDA- or EMA-approved drug, and this page is educational, not medical advice.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 5-10% topical serum/cream, applied twice daily
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen at −20 °C, protected from light and moisture. Reconstituted solution or finished serum refrigerated at 2-8 °C, kept out of direct light, and used within roughly 4 weeks. Acetyl hexapeptide-8 in solution is sensitive to heat and oxidation, so finished cosmetic formulations are typically buffered and stored cool and dark.
Half-life: No meaningful systemic half-life — it is topical and <1% penetrates skin; cosmetic effect builds over ~15-30 days and reverses over days to weeks after stopping.
Route: Topical (5-10% serum/cream, twice daily). The subcutaneous reconstitution figures on this page are an educational measurement reference only, not a real route.
Status: Not an FDA/EMA-approved drug. Regulated as a cosmetic ingredient (INCI Acetyl Hexapeptide-8); reviewed by CIR as safe as used. Educational use only.
About Argireline
Argireline (acetyl hexapeptide-8, also historically called acetyl hexapeptide-3) is a topically applied cosmetic peptide engineered to soften expression lines by partially inhibiting the SNARE machinery that drives muscle contraction, an action loosely analogous to a much milder, reversible, non-injected botulinum-toxin effect [1][3]. In every published cosmetic study it is used topically, not injected: the standard real-world Argireline dosage is a 5-10% (typically 10%) leave-on serum or oil-in-water emulsion massaged into the skin twice daily, usually morning and evening, over expression-line areas such as crow's feet, forehead, and glabella [1][2].\n\nThere is no clinically validated injectable or oral dose for this compound. The subcutaneous reconstitution figures below are an educational measurement reference only — they exist so the site's calculator can express a consistent vial-and-water workflow, the same way it does for oral and topical compounds. For this educational model we treat a 10 mg vial reconstituted with 2.0 mL of bacteriostatic water (5 mg/mL, 50 mcg per U-100 insulin-syringe unit), giving illustrative reference amounts of 250 mcg (5 units), 500 mcg (10 units), and 750 mcg (15 units). These numbers do not correspond to how Argireline is actually applied; in practice the peptide is dissolved into a serum base at 5-10% and applied to the skin surface.\n\nFrequency: Twice daily topical application (modeled here as 14 doses per week). Argireline is not FDA- or EMA-approved as a drug; it is a cosmetic ingredient presented for educational purposes only and is not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner glass wall of the 10 mg Argireline vial; do not aim the stream directly at the powder and do not shake, because peptides are sensitive to mechanical and oxidative degradation.
Gently swirl or roll the vial until the solution is completely clear; this yields a 5 mg/mL concentration, equal to 50 mcg per U-100 insulin-syringe unit.
Store the reconstituted solution refrigerated at 2-8 °C and protected from light; for this educational reference, 250 mcg ≈ 5 units, 500 mcg ≈ 10 units, and 750 mcg ≈ 15 units.
Educational note: Argireline is clinically and cosmetically a TOPICAL peptide applied as a 5-10% serum twice daily — these subcutaneous reconstitution figures are a measurement convention only and are not a recommended injection protocol; for real-world use the peptide is incorporated into a leave-on serum base rather than injected.
Interactive Argireline Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Introductory educational reference (≈5 units) | 250 mcg | 5 units (0.05 mL) |
| Standard educational reference (≈10 units) | 500 mcg | 10 units (0.10 mL) |
| Upper educational reference (≈15 units) | 750 mcg | 15 units (0.15 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Argireline, 10 mg each):
- checkAt the 500 mcg standard educational reference, twice daily, each 10 mg vial supplies about 20 doses (~1.4 weeks).
- check8-week course: approximately 6 vials.
- check12-week course: approximately 9 vials.
- check16-week course: approximately 12 vials.
Insulin Syringes (U-100):
- checkOne syringe per modeled dose, twice daily = 14 per week.
- check8-week course: about 112 syringes.
- check12-week course: about 168 syringes.
- check16-week course: about 224 syringes.
Bacteriostatic Water (30 mL bottles): Use 2.0 mL per vial for reconstitution.
- checkEach 10 mg vial uses 2.0 mL, so one 30 mL bottle reconstitutes about 15 vials.
- check8-week course (~6 vials = 12 mL): one 30 mL bottle.
- check12-week course (~9 vials = 18 mL): one 30 mL bottle.
- check16-week course (~12 vials = 24 mL): one 30 mL bottle.
Alcohol Swabs: Used to wipe the vial stopper and prep the modeled site before each draw.
- checkRoughly 1-2 swabs per dose.
- check8-week course: about 150 swabs.
- check12-week course: about 220 swabs.
- check16-week course: about 300 swabs.
Mechanism of Action (MOA)
Argireline is a synthetic acetylated, C-terminally amidated hexapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (acetyl hexapeptide-8), with a molecular weight near 889 g/mol. Its sequence reproduces the N-terminal six residues of SNAP-25 (synaptosomal-associated protein, 25 kDa), one of the three core proteins of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex that mediates calcium-dependent fusion of neurotransmitter vesicles at the neuromuscular junction [1][3].\n\nMechanistically, Argireline acts as a competitive mimic of native SNAP-25. By occupying the position that SNAP-25 would take in the assembling ternary SNARE complex (with syntaxin and VAMP/synaptobrevin), it destabilizes complex formation and dampens the docking and fusion of acetylcholine-containing vesicles. The downstream consequence is reduced acetylcholine release at the synapse, less intense muscle fiber contraction, and therefore a softening of dynamic expression lines [1][3]. This is fundamentally different from botulinum neurotoxin type A, which enzymatically and irreversibly cleaves SNAP-25. Blanes-Mira and colleagues found that Argireline inhibited neurotransmitter release with a potency comparable to botulinum toxin A but with far lower efficacy, which is precisely why it is considered a milder, reversible, non-toxic cosmetic alternative rather than a clinical neuromodulator [1].\n\nPharmacokinetics for Argireline are dominated by the skin barrier rather than systemic distribution. The peptide is hydrophilic, relatively large, and carries net charge (it exists in zwitterionic form at skin pH), and all three properties impair passage through the lipophilic stratum corneum. In vitro and ex vivo permeation studies consistently show that the great majority of applied peptide remains on the surface or within the stratum corneum, with typically less than 1% reaching viable epidermis and essentially none detected in the dermis [4][5]. Because so little crosses into circulation, Argireline has no clinically meaningful systemic plasma half-life; like other small peptides, any fraction that did reach the bloodstream would be rapidly degraded by tissue and serum peptidases within minutes. The functionally relevant timescale is therefore cosmetic and reversible: visible smoothing builds over roughly 15 to 30 days of consistent twice-daily use and gradually fades over days to weeks after the product is stopped [1][2].\n\nThis penetration limitation is the central practical caveat. Research groups have pursued strategies — molecular modification to reduce the peptide's charge, encapsulation in nanoliposomes, penetration enhancers, and microneedle delivery — specifically to push more peptide past the stratum corneum and improve performance [3][4][5]. In standard leave-on formulations, the realistic expectation is a modest, gradual softening of fine dynamic lines rather than the pronounced effect of injectable neuromodulators.\n\nThe real-world route is topical; the subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a clinically validated delivery method. Argireline is not approved as a drug by any major regulator and is sold and used as a cosmetic ingredient [6].
Clinical Trial Efficacy Highlights
- starBlanes-Mira and colleagues (2002, International Journal of Cosmetic Science) introduced the hexapeptide Ac-EEMQRR-NH2 (Argireline) from a rational design program, showed it inhibited calcium-dependent catecholamine release by interfering with SNARE-complex formation with a potency similar to but efficacy far below botulinum toxin A, and reported that an oil/water emulsion containing 10% of the peptide reduced wrinkle depth by up to roughly 30% after 30 days of treatment in healthy women volunteers [1].
- starWang and colleagues (2013, American Journal of Clinical Dermatology) conducted a randomized, placebo-controlled study of a 10% Argireline solution applied twice daily in Chinese subjects and reported significant improvement in periorbital and forehead wrinkle parameters versus vehicle over the treatment period, supporting topical efficacy beyond the original manufacturer data [2].
- starLim, Sun, Madanagopal, Rosa and Kang (2018, Scientific Reports) summarized that Argireline has been reported to reduce wrinkles by up to about 48% after four weeks of twice-daily use while being safer than botulinum toxin, but documented that the unmodified peptide permeates skin poorly; chemically modified analogues (Arg2 and Arg3) achieved markedly enhanced human skin permeation in vitro [3][5].
- starA 2025 review in the International Journal of Molecular Sciences on acetyl hexapeptide-8 in cosmeceuticals concluded that controlled studies support a measurable but modest anti-wrinkle effect at around 10% concentration, while emphasizing that poor stratum-corneum permeability is the main factor limiting real-world performance and a major focus of delivery-system research [3].
- starMortazavi and Moghimi (2022, International Journal of Cosmetic Science) argued that skin permeability is a frequently overlooked prerequisite for anti-wrinkle peptide performance, noting that charged, hydrophilic peptides like acetyl hexapeptide-8 are largely retained in the stratum corneum and that formulation strategy, not just concentration, governs whether clinical benefit is achieved [4].
- starA 2023 study (PMC10665711) evaluating an Argireline-containing serum formulated with hyaluronic acid, assessed objectively with the Visia Complexion Analysis system, reported measurable improvement in surface wrinkle metrics with twice-daily use, illustrating that pairing the peptide with hydrating and delivery-supportive vehicles is a common practical approach [7].
- starIndependent reviews of topical peptides for aged skin (Gorouhi and Maibach, 2009, International Journal of Cosmetic Science) place Argireline among neurotransmitter-inhibiting cosmetic peptides with plausible mechanism and supportive but largely manufacturer-derived or small-scale evidence, cautioning that large, long-term independent randomized trials remain limited [8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningTopical Argireline is generally very well tolerated; the most commonly reported effects are mild, transient local reactions such as slight stinging, redness, dryness, or tightness at the application site, usually related to the serum base rather than the peptide itself [6].
- warningAllergic or irritant contact dermatitis is possible but uncommon; a patch test before regular facial use is prudent, particularly for sensitive or reactive skin [6].
- warningAvoid application to broken, inflamed, or compromised skin, and keep the product away from the eyes and mucous membranes, since the surrounding eye area is a frequent target zone and direct ocular contact can cause irritation.
- warningBecause less than about 1% of the peptide penetrates beyond the stratum corneum, meaningful systemic absorption and systemic side effects are not expected from normal cosmetic use; this also means the effect is modest and reverses within days to weeks of stopping [4][5].
- warningEfficacy is gradual and partial: realistic results are a subtle softening of fine dynamic lines over weeks, not the pronounced, sustained effect of injectable botulinum toxin, and benefit is maintained only with continued use [1][2].
- warningSafety in pregnancy and breastfeeding has not been established; as with most cosmetic actives lacking such data, caution or avoidance is commonly advised, and individuals should consult a clinician.
- warningThe subcutaneous reconstitution figures on this page are an educational measurement convention only. Injecting cosmetic peptides or non-sterile, preservative-containing cosmetic raw materials is unsafe and is not a recommended or studied route of administration.
- warningRegulatory/research status: Argireline (INCI Acetyl Hexapeptide-8) is NOT an FDA- or EMA-approved drug. It is regulated as a cosmetic ingredient, has been reviewed by the Cosmetic Ingredient Review panel as safe as used in cosmetics, and is presented here for educational purposes only [6].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Argireline dosage?expand_more
The typical real-world Argireline dosage is topical: a 5-10% (most commonly 10%) leave-on serum or oil-in-water emulsion applied to expression-line areas twice daily, morning and evening. Controlled topography studies used 10% formulations and reported up to roughly 30% reduction in wrinkle depth after 30 days [1][2]. There is no established injectable or oral dose; the subcutaneous mcg figures on this page are an educational measurement reference only, not a recommended route.
Is Argireline FDA approved?expand_more
No. Argireline (acetyl hexapeptide-8) is not an FDA- or EMA-approved drug. It is regulated as a cosmetic ingredient (INCI: Acetyl Hexapeptide-8) and has been reviewed by the Cosmetic Ingredient Review panel as safe as used in cosmetics. Cosmetic ingredients in general are not 'FDA approved' the way drugs are. Treat all information here as educational, not medical advice [6].
How do you reconstitute Argireline, and is reconstitution even relevant for a topical peptide?expand_more
In real cosmetic use you do not inject Argireline — the peptide is dissolved into a serum or cream base at 5-10%. For this site's standardized educational model only, a 10 mg vial is reconstituted with 2.0 mL of bacteriostatic water to give 5 mg/mL (50 mcg per U-100 unit). That Argireline reconstitution figure exists so the calculator can show consistent vial-and-water math; it is not an instruction to inject the peptide.
What is the half life of Argireline?expand_more
Argireline has no clinically meaningful systemic half-life because it is a topical peptide and typically less than 1% penetrates beyond the stratum corneum, so almost none reaches the bloodstream [4][5]. Any small peptide fraction that did reach circulation would be degraded by peptidases within minutes. The practical timescale is cosmetic: visible smoothing builds over about 15-30 days of twice-daily use and reverses over days to weeks after stopping [1].
What are the main Argireline side effects, and can it be stacked with other actives?expand_more
Topical Argireline is well tolerated; reported side effects are mostly mild local stinging, redness, dryness, or tightness, with rare contact irritation — a patch test is sensible [6]. It is commonly layered (stacked) with hydrating and barrier ingredients such as hyaluronic acid, and serums often pair it with peptides like Matrixyl or with niacinamide [7]. Avoid the eyes and broken skin, and avoid the unstudied, unsafe injection route implied only as an educational model here.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Argireline, plus the universal dosing calculator.
Academic References & Study Citations
Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. View Scientific Paper →
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. PMID: 23417317. View Scientific Paper →
Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025;26(12):5722. View Scientific Paper →
Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022;44(2):232-248. doi:10.1111/ics.12770. View Scientific Paper →
Lim SH, Sun Y, Madanagopal TT, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 2018;8:1500. doi:10.1038/s41598-017-18454-z. PMC5785486. View Scientific Paper →
Cosmetic Ingredient Review (CIR) Expert Panel. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. 2020. View Scientific Paper →
Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis. 2023. PMC10665711. View Scientific Paper →
Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. doi:10.1111/j.1468-2494.2009.00490.x. View Scientific Paper →